This patent document pertains generally to cardiac rhythm or function management devices, and more particularly, but not by way of limitation, to atrioventricular delay adjustment enhancing ventricular tachyarrhythmia detection.
Cardiac rhythm or function management devices include implantable devices to help maintain heart rhythm or function. Such devices can include pacers, defibrillators, cardioverters, cardiac resynchronization therapy (CRT), or various combinations of such devices. Such devices can typically sense intrinsic heart contractions, deliver pacing pulses to evoke responsive heart contractions, or deliver a shock to interrupt certain arrhythmias. This can help improve the patient's heart rhythm or can help coordinate a spatial nature of the heart contraction, either of which may improve cardiac output of blood to help meet the patient's metabolic need for such cardiac output.
For example, detecting a ventricular tachyarrhythmia (e.g., a too-fast ventricular heart rhythm) often involves detecting a rate of ventricular heart contractions that exceeds a tachyarrhythmia rate threshold. By using multiple tachyarrhythmia rate thresholds, multiple tachyarrhythmia rate zones can be established, which can further classify different tachyarrhythmias based on which zone the heart rate falls within.
The present inventors have recognized that one problem with ventricular tachyarrhythmia detection is when an atrial pace is delivered at a heart rate that falls within one or more of the tachyarrhythmia rate zones. Such a “fast” atrial pace can inhibit detection of a tachyarrhythmic intrinsic ventricular contraction that occurs close in time to the fast atrial pace. This, in turn, can prevent proper diagnosis or treatment of a ventricular tachyarrhythmia. The present inventors have recognized an unmet need for improved apparatuses or methods for avoiding such problems.
This overview is intended to provide an overview of the subject matter of the present patent application. It is not intended to provide an exclusive or exhaustive explanation of the invention. The detailed description is included to provide further information about the subject matter of the present patent application.
This document describes devices and methods for enhancing detection of tachyarrhythmia. A device example includes an atrial sensing circuit, a ventricular sensing circuit and an atrioventricular (AV) delay adjustment circuit. The atrial sensing circuit detects a first fast atrial pace that concludes a timing interval that is shorter than or equal to a first threshold value. The ventricular sensing circuit detects a first condition that comprises a sensed intrinsic first fast ventricular contraction that occurs within a specified first period of a most recently detected first fast atrial pace. The fast ventricular contraction concludes a timing interval that is shorter than or equal to a second threshold value. The AV delay adjustment circuit attempts to decrease an AV delay at least in part in response to detecting the first condition.
A method example includes detecting a first fast atrial pace that concludes a timing interval that is shorter than or equal to a first threshold value, detecting a first condition that includes a sensed intrinsic first fast ventricular contraction occurring within a specified first period of a most recently detected first fast atrial pace that concludes a timing interval that is shorter than or equal to a second threshold value; and attempting to decrease an atrioventricular (AV) delay at least in part in response to detecting the first condition.
In the drawings, which are not necessarily drawn to scale, like numerals describe substantially similar components throughout the several views. Like numerals having different letter suffixes represent different instances of substantially similar components. The drawings illustrate generally, by way of example, but not by way of limitation, various embodiments discussed in the present document.
The following detailed description includes references to the accompanying drawings, which form a part of the detailed description. The drawings show, by way of illustration, specific embodiments in which the invention may be practiced. These embodiments, which are also referred to herein as “examples,” are described in enough detail to enable those skilled in the art to practice the invention. The embodiments may be combined, other embodiments may be utilized, or structural, logical and electrical changes may be made without departing from the scope of the present invention. The following detailed description is, therefore, not to be taken in a limiting sense, and the scope of the present invention is defined by the appended claims and their equivalents.
In this document, the terms “a” or “an” are used, as is common in patent documents, to include one or more than one. In this document, the term “or” is used to refer to a nonexclusive or, unless otherwise indicated. Furthermore, all publications, patents, and patent documents referred to in this document are incorporated by reference herein in their entirety, as though individually incorporated by reference. In the event of inconsistent usages between this document and those documents so incorporated by reference, the usage in the incorporated reference(s) should be considered supplementary to that of this document; for irreconcilable inconsistencies, the usage in this document controls.
Signals picked up by electrode 20 are applied to an atrial sense amplifier 34 forming a part of the CRMD 10. Likewise, signals from the LV lead 28 are applied to a left ventricle sense amplifier 36. Conductors in the RV lead 16 connect to the electrodes 24 and 26 and carry signals relating to depolarization of the RV to a right ventricular sense amplifier 38.
The sense amplifiers 34, 36 and 38 may include signal processing circuitry for amplifying or shaping analog signals picked up by the electrodes in and on the heart and these analog signals are applied to an analog-to-digital converter forming a part of a controller 40. Controller 40 may include a digital signal processor, application specific integrated circuit (ASIC), microprocessor, or other type of processor, interpreting or executing instructions in software or firmware. In a rate adaptive CRMD, a physiologic sensor, such as accelerometer 39, is also provided. A crystal controlled clock 42 provides timing signals to the controller 40. Also coupled to the controller 40 by an address bus (ADD), a data bus (DATA), and control bus (CONT) are a read-only memory (ROM) 44, a random access memory (RAM) 46 and an input/output interface (I/O) 48. A telemetry circuit 50 is coupled to the I/O circuit 48 by a bi-directional bus 52 and functions to allow a two-way communication with an external programmer/monitor 54.
In certain examples, the ROM memory 44 stores instructions executable by the controller 40. The executable instructions form a program which when executed by the controller 40 functions to control a pulse generator 56, such as by causing it to issue cardiac stimulating pulses over the leads 16 and 28 in order to initiate depolarization of the right atrium, the right ventricle, and the left ventricle at times determined by the controller 40.
Using the external programmer 54 and the telemetry capabilities of the CRMD 10, a medical professional can program into the CRMD 10 various operating parameters via the RAM memory 46.
In some examples, dual-chamber pacemakers allow programming of pacing modes, lower rate limits, pulse width, pulse amplitude, sensitivity, refractory periods, maximum tracking rate, AV delay and other parameters. Among pacemaker patients who are chronotropically incompetent (e.g., unable to increase sinus node rate appropriately with exercise), rate-responsive pacemakers may allow for increases in pacing rates with exercise. Appropriately adjusting a device response to exercise can be challenging. For programming rate-response capability, some CRMDs include procedures for initial programming of rate-response parameters, subsequent automatic adjustment of these parameters, and retrievable diagnostic data, via the telemetry link, to assess the appropriateness of the rate response. Rate-responsive pacemakers may require programmable features to regulate the relation between a sensor output and pacing rate and to limit the maximum sensor-driven pacing rate, i.e., the URL. These programmable parameters may need to be individually adjusted for each patient, and the choice of one programmable parameter will often depend on the availability of another parameter. For example, in a patient with complete AV block and paroxysmal atrial fibrillation, a dual-chamber pacemaker not having a mode-switching capability most appropriately would be programmed to its DDIR mode, whereas in the same patient, a pacemaker with mode-switching capability most appropriately would be programmed to its DDDR mode with mode switching.
When non-physiological atrial tachyarrhythmias, such as atrial fibrillation or flutter, occur paroxysmally in a patient with a dual-chamber pacemaker programmed to conventional DDD or DDDR mode, the tachyarrhythmia may be tracked near the programmed maximum tracking rate (MTR), leading to an undesirable acceleration of ventricular pacing rate. Some dual chamber devices detect rapid, non-physiological atrial rates and automatically switch modes to one that does not track atrial activity, such as DDI or DDIR. When the atrial tachyarrhythmia terminates, the pacemaker automatically reverts back to its DDD or DDDR mode.
Referring to
The AV delay value, here 300 ms, is a parameter programmed in by the physician and this establishes the time of occurrence of the A-pace (AP) pulse produced by the implantable device. The diagram of
Referring again to
From what has been explained with the aid of
Tachyarrhythmia is sometimes categorized into three rate zones—VF, VT, and VT-1. Zone VF is for ventricular fibrillation and is the highest rate zone. Zone VT is for ventricular tachycardia. Zone VT-1 is sometimes referred to as slow tachy. A programmed interval referred to as the “lowest tachy zone interval” defines the lower boundary of the VT-1 rate zone. It is the longest interval (slowest rate) that sensed beats can have and be classified as a tachycardia. This parameter varies from patient-to-patient and is arrived at by observing ECG data for the patient over a period of time.
The timing diagram of
To avoid under-sensing, a tachyarrhythmia detection feature limits the A-V delay and limits the pacing rate. The detection feature insures that the A-pace, the V-pace and the associated refractory periods fall outside the ventricular tachyarrhythmia zones. This reduces the chance that ventricular tachyarrhythmia events will be under-sensed due to the refractory periods and enhances ventricular tachyarrhythmia detection.
In some examples, the detection feature is automatically activated when conditions for entry into the feature are satisfied. In some examples, the detection feature is only automatically activated under certain conditions. For instance, if the device is a cardiac function management (CFM) device, the CFM device may be in DDD(R) or DDI(R) pacing mode, and the pacing state of the CFM device is preferably normal, post-shock, post atrial therapy, or in anti-tachy response (ATR). The detection feature should not be activated in a user-activated temporary state such as temporary bradycardia pacing or in a user activated device test state such as a user-commanded pacing threshold test. If conditions for exiting the feature are satisfied, the feature is deactivated and no longer limits the A-V delay and pacing rate. In some examples, the detection feature is exited if the device enters a programming mode that does not support the detection feature.
Referring to
Returning to
In determining whether the first condition is satisfied, the number of ventricular events to time the specified period should be counted relative to the latest fast atrial pace. For example, if the specified first period is three cardiac cycles and if a second fast atrial pace occurs before the fast VVs is detected, the specified first period is three cardiac cycles after the latest fast atrial pace. In some examples, the cardiac cycle count is reset after the second fast atrial pace.
If the first condition does occur, the method 500 may include detecting a second condition at block 520 before the decrease in AV delay is attempted. The second condition follows the first condition (e.g., the second condition follows the first detected fast VVs interval). At block 522, the second condition includes detecting a second fast atrial pace within a specified second period of detecting the first condition. An example of a second condition is illustrated in
Returning to
In some examples, the timing interval begins with a ventricular event (sense or pace) and ends with an atrial pace (VAp). The first threshold value is an interval that is shorter than or equal to a lowest-rate tachyarrhythmia rate interval threshold. The atrial sensing circuit comparator 720 detects a fast atrial pace that results in a VAp interval shorter than or equal to the lowest-rate tachyarrhythmia rate interval threshold.
The ventricular sensing circuit 710 includes a ventricular sensing circuit timer 730 and a ventricular sensing circuit comparator 735. The ventricular sensing circuit comparator 735 detects a first condition. The first condition includes a sensed intrinsic first fast ventricular contraction Vs that occurs within a specified first period of a most recently detected first fast atrial pace. In some examples, the first specified period is a specified number of cardiac cycles. The fast ventricular contraction concludes a timing interval that is shorter than or equal to a second threshold value 740. In some examples, the second threshold value is an interval (VVs) that is shorter than or equal to a lowest-rate tachyarrhythmia rate interval threshold. The apparatus 700 also includes an atrioventricular (AV) delay adjustment circuit 745. The AV delay adjustment circuit decreases an AV delay at least in part in response to detecting the first condition.
In certain examples, the apparatus 700 optionally detects the second condition. The atrial sensing circuit timer 715 and the atrial sensing circuit comparator 720 detect a second fast atrial pace within a specified second period of detecting the first condition. The second condition is declared if the ventricular sensing circuit timer 730 and the ventricular sensing circuit comparator 735 detect a second fast intrinsic ventricular contraction that occurs within a specified third period of a most recently detected second fast atrial pace. The AV delay adjustment circuit attempts to decrease the AV delay in response to detecting both the first and second conditions.
In some examples, the apparatus 700 includes a state machine 750. The state machine 750 provides first, second, and third operating states.
If a first condition is not detected, the state machine 750 continues at 805 waiting for the first condition. If the first condition is detected, a first trigger 810 transitions the state machine 750 from the first operating state 805 to the second operating state 815. In some examples, the first condition includes a sensed intrinsic first fast ventricular contraction (Vs) that occurs within a specified first period of a most recently detected first fast atrial pace (VAp). The first period may be specified in terms of a number of cardiac cycles. The Vs concludes a time interval from the ventricular event of the fast atrial pace to the ventricular sense (VVs). The first condition is satisfied if the VVs interval is shorter than or equal to a second threshold value, such as the lowest-rate tachyarrhythmia rate interval threshold for example.
If a second condition is detected, a second trigger 820 transitions the state machine 750 to the third operating state 825. In some examples, the second condition includes a fast atrial pace (a fast VAp interval) defined by the lowest tachyarrhythmia rate zone interval. The fast VAp interval occurs within a specified second period of the VVs interval of the first condition. The second condition also includes a second fast intrinsic ventricular contraction (VVs) that occurs within a specified third period of the most recently detected second fast atrial pace (VAp). The third operating state 825 includes attempting to decrease the AV delay.
If, while in the second operating state 815, the second condition is not detected within a specified fourth period after transitioning to the second operating state 815, a third trigger 830 transitions the state machine 750 to the first operating state 805, where the state machine 750 resumes waiting for the first condition to occur. If some cases the first part of the second condition, the fast VAp interval may be detected but not the second fast intrinsic ventricular contraction corresponding to the second VVs interval. If the second fast intrinsic ventricular contraction does not occur within a specified fifth period, a fourth trigger 835 transitions the state machine 750 to the first operating state 805.
When the state machine 750 enters the third operating state 825, the tachyarrhythmia detection feature is activated. The detection feature determines a desired current cardiac cycle interval (CCI) and a ventricular event to atrial pace interval (VAp) that enhances tachyarrhythmia detection. In some examples, a marker is stored or communicated to a second device to indicate the activation. The AV delay adjustment circuit 745 attempts to decrease the AV delay. In some examples, the AV delay adjustment circuit 745 includes a specified minimum AV delay. For example, this minimum delay may be a programmed parameter. In some examples, the AV delay adjustment circuit 745 attempts to decrease the AV delay while preserving the specified minimum AV delay.
The AV delay adjustment circuit 745 determines a minimum and a maximum VAp intervals.
At block 1010, a fourth condition is detected. The fourth condition includes the safe sensing VAp timing interval being shorter than or equal to the maximum extended VAp timing interval. At block 1015, a VAp escape timing interval equal is set equal to the safe sensing VAp timing interval if the third and fourth conditions are detected (i.e., VAp=ss13VAp).
If the third condition is detected but the fourth condition is absent, at block 1020, the VAp escape timing interval is set equal to the safe sensing VAp timing interval (i.e., VAp=ss13VAp). Additionally, at block 1025, the next CCI is set equal to the current CCI plus the safe sensing VAp timing interval less the maximum extended VAp timing interval (i.e., CCI=CCI+(ss13VAp−me13VAp)). If both the third and fourth conditions are absent, the method 1000 includes leaving the VAp escape timing interval unchanged from an existing value of the VAp escape timing interval.
Returning to
In some examples, the apparatus 700 may be a CFM device that provides bi-ventricular pacing. If the LV offset is programmed to be a negative value with respect to the RV offset, it may be preferable to program the LV offset to zero while the tachyarrhythmia detection feature is active. This may avoid unwanted or unintended interactions of the LV offset with the tachyarrhythmia detection feature.
In some examples, the various functions described herein can be implemented as modules. Modules can be software, hardware, firmware or any combination thereof. Multiple functions can be performed in one or more modules as desired, and the embodiments described are merely examples. The software and/or firmware are typically executed on a processor. For example, the processor may be included in the controller 40 of the CRMD 10 of
In some examples, the tachyarrhythmia detection feature is exited if a number of number of consecutive slow ventricular cycles are present for a specified sixth period. In some examples, the tachyarrhythmia detection feature is exited if ten consecutive slow ventricular timing intervals are present. In some examples, a ventricular timing interval is slow if it exceeds the lowest-rate tachyarrhythmia rate interval threshold.
It is to be understood that the above description is intended to be illustrative, and not restrictive. For example, the above-described embodiments (and/or aspects thereof) may be used in combination with each other. Many other embodiments will be apparent to those of skill in the art upon reviewing the above description. The scope of the invention should, therefore, be determined with reference to the appended claims, along with the full scope of equivalents to which such claims are entitled. In the appended claims, the terms “including” and “in which” are used as the plain-English equivalents of the respective terms “comprising” and “wherein.” Also, in the following claims, the terms “including” and “comprising” are open-ended, that is, a system, device, article, or process that includes elements in addition to those listed after such a term in a claim are still deemed to fall within the scope of that claim. Moreover, in the following claims, the terms “first,”“second,” and “third,” etc. are used merely as labels, and are not intended to impose numerical requirements on their objects.
The Abstract is provided to comply with 37 C.F.R. §1.72(b), which requires that it allow the reader to quickly ascertain the nature of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims. Also, in the above Detailed Description, various features may be grouped together to streamline the disclosure. This should not be interpreted as intending that an unclaimed disclosed feature is essential to any claim. Rather, inventive subject matter may lie in less than all features of a particular disclosed embodiment. Thus, the following claims are hereby incorporated into the Detailed Description, with each claim standing on its own as a separate embodiment.
This application is a Continuation-in-Part of U.S. application Ser. No. 10/274,697, filed Oct. 18, 2002 now U.S. Pat. No. 7,376,461, which is incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
4059116 | Adams | Nov 1977 | A |
4208008 | Smith | Jun 1980 | A |
RE30387 | Denniston, III et al. | Aug 1980 | E |
4432360 | Mumford et al. | Feb 1984 | A |
4503857 | Boute et al. | Mar 1985 | A |
4712556 | Baker, Jr. | Dec 1987 | A |
4860749 | Lehmann | Aug 1989 | A |
4928688 | Mower | May 1990 | A |
4941471 | Mehra | Jul 1990 | A |
4944298 | Sholder | Jul 1990 | A |
4972834 | Begemann et al. | Nov 1990 | A |
4998974 | Aker | Mar 1991 | A |
5129394 | Mehra | Jul 1992 | A |
5183040 | Nappholz et al. | Feb 1993 | A |
5331966 | Bennett et al. | Jul 1994 | A |
5334220 | Sholder | Aug 1994 | A |
5356425 | Bardy et al. | Oct 1994 | A |
5360437 | Thompson | Nov 1994 | A |
5365932 | Greenhut | Nov 1994 | A |
5379776 | Murphy et al. | Jan 1995 | A |
5417714 | Levine et al. | May 1995 | A |
5462060 | Jacobson et al. | Oct 1995 | A |
5523942 | Tyler et al. | Jun 1996 | A |
5549649 | Florio et al. | Aug 1996 | A |
5560369 | McClure et al. | Oct 1996 | A |
5560370 | Verrier et al. | Oct 1996 | A |
5607460 | Kroll et al. | Mar 1997 | A |
5620471 | Duncan | Apr 1997 | A |
5620473 | Poore | Apr 1997 | A |
5626623 | Kieval et al. | May 1997 | A |
5653738 | Sholder | Aug 1997 | A |
5690689 | Sholder | Nov 1997 | A |
5700283 | Salo | Dec 1997 | A |
5702424 | Legay et al. | Dec 1997 | A |
5713930 | van der Veen et al. | Feb 1998 | A |
5713932 | Gillberg et al. | Feb 1998 | A |
5716382 | Snell | Feb 1998 | A |
5724985 | Snell et al. | Mar 1998 | A |
5725559 | Alt et al. | Mar 1998 | A |
5730141 | Fain et al. | Mar 1998 | A |
5738096 | Ben-Haim | Apr 1998 | A |
5741308 | Sholder | Apr 1998 | A |
5749906 | Kieval et al. | May 1998 | A |
5776167 | Levine et al. | Jul 1998 | A |
5782887 | van Krieken et al. | Jul 1998 | A |
5788717 | Mann et al. | Aug 1998 | A |
5792193 | Stoop | Aug 1998 | A |
5792200 | Brewer | Aug 1998 | A |
5800464 | Kieval | Sep 1998 | A |
5800471 | Baumann | Sep 1998 | A |
5814077 | Sholder et al. | Sep 1998 | A |
5814081 | Ayers et al. | Sep 1998 | A |
5836987 | Baumann et al. | Nov 1998 | A |
5840079 | Warman et al. | Nov 1998 | A |
5861007 | Hess et al. | Jan 1999 | A |
5873895 | Sholder et al. | Feb 1999 | A |
5873897 | Armstrong et al. | Feb 1999 | A |
5893882 | Peterson et al. | Apr 1999 | A |
5897575 | Wickham | Apr 1999 | A |
5931856 | Bouhour et al. | Aug 1999 | A |
5935081 | Kadhiresan | Aug 1999 | A |
5944744 | Paul et al. | Aug 1999 | A |
5978710 | Prutchi et al. | Nov 1999 | A |
5983138 | Kramer | Nov 1999 | A |
6026320 | Carlson et al. | Feb 2000 | A |
6044298 | Salo et al. | Mar 2000 | A |
6049735 | Hartley et al. | Apr 2000 | A |
6052620 | Gillberg et al. | Apr 2000 | A |
6081747 | Levine et al. | Jun 2000 | A |
6088618 | Kerver | Jul 2000 | A |
6091988 | Warman et al. | Jul 2000 | A |
6122545 | Struble et al. | Sep 2000 | A |
6128533 | Florio et al. | Oct 2000 | A |
6151524 | Krig et al. | Nov 2000 | A |
6233485 | Armstrong et al. | May 2001 | B1 |
6246909 | Ekwall | Jun 2001 | B1 |
6263242 | Mika et al. | Jul 2001 | B1 |
6266554 | Hsu et al. | Jul 2001 | B1 |
6292693 | Darvish et al. | Sep 2001 | B1 |
6408209 | Bouhour et al. | Jun 2002 | B1 |
6411847 | Mower | Jun 2002 | B1 |
6421564 | Yerich et al. | Jul 2002 | B1 |
6430439 | Wentkowski et al. | Aug 2002 | B1 |
6434424 | Igel et al. | Aug 2002 | B1 |
6438421 | Stahmann et al. | Aug 2002 | B1 |
6484058 | Williams et al. | Nov 2002 | B1 |
6501988 | Kramer et al. | Dec 2002 | B2 |
6731983 | Ericksen et al. | May 2004 | B2 |
7069077 | Lovett et al. | Jun 2006 | B2 |
7142915 | Kramer et al. | Nov 2006 | B2 |
7142918 | Stahmann et al. | Nov 2006 | B2 |
7184834 | Levine | Feb 2007 | B1 |
7283872 | Boute et al. | Oct 2007 | B2 |
7376461 | Perschbacher et al. | May 2008 | B2 |
20010014817 | Armstrong et al. | Aug 2001 | A1 |
20020120298 | Kramer et al. | Aug 2002 | A1 |
20030069610 | Kramer et al. | Apr 2003 | A1 |
20030078630 | Lovett et al. | Apr 2003 | A1 |
20030233131 | Kramer et al. | Dec 2003 | A1 |
20040010295 | Kramer et al. | Jan 2004 | A1 |
20040077963 | Perschbacher et al. | Apr 2004 | A1 |
20050283196 | Bocek et al. | Dec 2005 | A1 |
20090149907 | Perschbacher et al. | Jun 2009 | A1 |
Number | Date | Country |
---|---|---|
0033418 | Aug 1981 | EP |
0360412 | Mar 1990 | EP |
0401962 | Dec 1990 | EP |
0597459 | May 1994 | EP |
0617980 | Oct 1994 | EP |
0748638 | Dec 1996 | EP |
1480715 | Sep 2009 | EP |
WO-0071200 | Nov 2000 | WO |
WO-0071202 | Nov 2000 | WO |
WO-0071203 | Nov 2000 | WO |
Number | Date | Country | |
---|---|---|---|
20070142869 A1 | Jun 2007 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 10274697 | Oct 2002 | US |
Child | 11676464 | US |